New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 5, 2014
07:35 EDTLPTNLpath's Lpathomab for traumatic brain injury receives $1.7M development grant
Lpath received official notification from the National Institutes of Neurological Diseases and Stroke that it has been awarded a $1.7M, 2.5-year grant to develop its antibody therapeutic, Lpathomab against the bioactive lipid lysophosphatidic acid for the treatment of traumatic brain injury. The Phase l amount of $224K will fund studies designed to repeat in rats the efficacy previously demonstrated in a controlled-cortical-impact model of TBI. Contingent on Phase I success, Phase II funds of almost $1.5M will be used to advance Lpathomab through safety, pharmacology, and toxicology studies needed to file an IND.
News For LPTN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 20, 2014
08:12 EDTLPTNLpath granted patent for iSONEP and ASONEP programs in Europe
Subscribe for More Information
October 14, 2014
16:34 EDTLPTNLpath files to sell 3.6M shares of common stock for holders
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use